tbuckley/cabot-search huggingface dataset:
FATALITY OF THE RATTLESNAKE.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nonmyeloablative stem cell transplantation for congenital immunodeficiencies
Authors: Persis Amrolia, Hubert B. Gaspar, Amel Hassan, David Webb, Alison Jones, Natalie Sturt, Giorgina Mieli-Vergani, Antonio Pagliuca, Ghulam Mufti, Nedim Hadzic, Graham Davies, Paul Veys
Journal: Blood (2000)
The Proceedings of the Committee of Council
Authors: W. C. Grigg
Journal: BMJ (1878)

<h3>Abstract</h3> We propose a novel <b>Timed Intervention</b> exended SEIR model for predicting the evolution of the Covid 19 Pandemic in the USA. The model can, by sparameter, assignment, be reduced to the model of Peng et al, which appeared in February, 2020 (Reference [2]). Novel aspects of the proposed model include Formulation of a “Protected” population <i>P</i>, which can be viewed as a “Sheltered in Place”, unexposed population which, starting at time <i>t</i> = <i>τ<sub>P</sub></i>, builds up and stores a reservoir of unexposed Population; This “Protection Intervention” provides the basis for a second Timed Release Intervention: on receiving a “reopening signal” at time <i>t</i> = <i>τ<sub>R</sub></i>, this second intervention initiates a release of this stored population back into the general population <i>S</i>.; Selection of model parameters to optimize the approximation of the model up to the present, and then projecting simulation of the model based on the value thus obtained 100,200, 365, and 730 days into the future. This model shows excellent qualitative results and quantitative results that are good, considering the chosen nationwide scope. These results compare favorably to University of Washington IHME [5] projections, as published Daily on the http://Worldometers.info website. The qualitative and quantitative behavior of all 7 state variables <i>S, P, E, I, Q, R, D</i> will be illustrated and discussed, in this and future further Intervention cycles<sup>1</sup>
SRC Inhibition Overcomes Trastuzumab Resistance in HER2-Overexpressing Breast Cancers
Journal: Cancer Discovery (2011)

Late-recurring T-ALL can be a second leukemia.Significance: First evidence suggesting genetic predisposition.Impact: Second T-ALL might respond to first-line therapy. LeukemiaT-cell acute lymphoblastic leukemia (T-ALL) is a childhood disease that has an approximately 75% rate of 5-year eventfree survival.However, relapse often occurs on or just after treatment, and prognosis for these patients is very poor.In a recent article, Szczepanski and colleagues examined 22 patients with T-ALL that relapsed more than 2.5 years after diagnosis to determine whether these disease recurrences represented a second, independent disease.The authors found clonal T-cell receptor (TCR) rearrangements in 20 of the 22 patients.In 12 of these 20 patients, identical TCR rearrangements were seen at diagnosis and in the relapsed cancer.Strikingly, however, in the other 8 patients, the clonal TCR rearrangements seen at diagnosis were absent in the second disease.Comparative genomic hybridization array analysis showed that 7 of these 8 patients had completely different patterns of copy number variation between first and second disease.In the other patient, a well-known somatic microdeletion was observed.Finally, the authors were unable to detect any genetic markers of the second disease in samples of the original disease.These data suggest that a significant percentage of late relapsing T-ALL may in fact represent new disease, and it is possible that these patients have a genetic predisposition to T-ALL development.
Lehrbuch der Gonorrhöe: Nebst einem Anhang—"Die Sterilität des Mannes."
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viewing the Journal of the National Cancer Institute
Authors: M. F. Stanton
Journal: CA A Cancer Journal for Clinicians (1970)

and associates (National Communicable Disease Center, At lanta, Georgia) collected data on all cases of leukemia diagnosed from 1956-67 in residents of metropolitan Atlanta.Negroes over age 70 had a reduced incidence of every type of leukemia when compared with whites of the same age group.This deficit among elderly Negroes probably reflects socioeconomic factors, in cluding less medical care, rather than a racial factor.[July]
Semaine des hôpitaux, Paris
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Prevention and control of influenza
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In this issue
Authors: Peter Kirkpatrick Senior, Alexandra Flemming, Charlotte Harrison, Sarah Crunkhorn Associate, Megan Cully Assistant, Katie Kingwell, Natasha Bray Senior, Mariam Faruqi, Susanne Harris, Catriona Editorial Assistants, Emily Finn, Rebecca Cromie, Judith Shadwell, Simon Fenwick, Patrick Morgan, Vicky Summersby, Natalie Smith, Arianne Heinrichs, Ritu Dhand, Alison Mitchell
Journal: Nature Reviews Drug Discovery (2014)
The crossover lung segment: congenital malformation associated with a variant of scimitar syndrome.
Authors: I Hyde
Journal: Thorax (1987)

The crossover lung segment: congenital malformation associated with a variant of scimitar syndrome SIR,-In their paper (June 1987;42:417-9) Drs BS Clements and JO Warner make the statement that the crossover lung segment in association with a variant of the scimitar syn- drome has not previously been described but this is incorrect.Their description is, in all essentials, that of horseshoe lung.'
Carbon monoxide yield of cigarettes.
Authors: D Colin-Jones, R Frost, Isaacson Gut
Journal: BMJ (1980)

assess this.We should be told how many patients receiving long-term anti-inflammatory therapy were examined in order to find the 249 patients who had no gastric lesions at the initial endoscopy, incorrectly named the pretreatment endoscopy.If few were rejected this would support the view that the lesions are often transient.We do not accept the authors' reasons for not including a control group, and would suggest the use of paracetamol in a group with osteoarthrosis.This is an important area of work in which much more information is required, but we would reluctantly question the conclusions drawn by these workers.Further studies of better design should be undertaken.
Erratum to: Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression
Authors: Xi Chen, Hannah V. McCue, Shi Quan Wong, Sudhanva S. Kashyap, Brian C. Kraemer, Jeff W. Barclay, Robert D. Burgoyne, Alan Morgan
Journal: Molecular Neurodegeneration (2015)

The original version of this article [1] unfortunately contained a mistake. The author list contained a spelling error for the author Hannah V. McCue. The original article has been corrected for this error. The corrected author list is given below:Xi Chen, Hannah V. McCue, Shi Quan Wong, Sudhanva S. Kashyap, Brian C. Kraemer, Jeff W. Barclay, Robert D. Burgoyne and Alan Morgan
Erotomania
Authors: DAVID E. RASKIN, KATHLEEN E. SULLIVAN
Journal: American Journal of Psychiatry (1974)

The unusual syndrome of erotomania consists of a delusional belief, usually in a woman, that an older man of higher social status is in love with her. The authors review the few cases of erotomania described in the literature and present two new cases. They also discuss some new dimensions in understanding this condition.
Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
Authors: William Ho, Nicole Nasrah, Dan Johnson
Journal: Journal of Clinical Oncology (2019)

TPS24 Background: Regulatory T cells (T reg ) can dampen anti-tumor immune responses in the tumor microenvironment (TME). The predominant chemokine receptor on human T reg is CCR4, the receptor for the chemokines CCL17 and CCL22, which are produced by tumor cells, tumor-associated macrophages and dendritic cells, as well as by effector T cells (T eff ) in the setting of an inflammatory anti-tumor response. Preclinical studies with orally-available CCR4 antagonists have demonstrated potent inhibition of T reg migration into tumors, an increase in the intratumoral T eff /T reg ratio, and anti-tumor efficacy as a single agent and in combination with checkpoint inhibitors. In a first-in-human trial conducted in healthy volunteers, the oral CCR4 antagonist FLX475 was demonstrated to be well tolerated with outstanding PK properties. A robust PD assay measuring receptor occupancy on circulating T reg demonstrated the ability to safely achieve exposure levels predicted to maximally inhibit T reg recruitment into tumors via CCR4 signaling. These human PK, PD, and safety data have enabled a streamlined design of a Phase 1/2 study of FLX475 in cancer patients both as monotherapy and in combination with checkpoint inhibitor. Methods: This clinical trial is a Phase 1/2, open-label, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study is being conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 (Phase 1) of the study, at least 3 to 6 eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab (Part 1b). In Part 2 (Phase 2) of the study, expansion cohorts of both checkpoint-naïve and checkpoint-experienced patients with tumor types predicted to be enriched for T reg and/or CCR4 ligand expression (i.e. “charged tumors”) -- including both EBV + and HPV + tumors and NSCLC, HNSCC, and TNBC -- will be enrolled using a Simon 2-stage design. As of November 6, 2018, Cohort 1 has been completed without DLT. Clinical trial information: NCT03674567.
Second International Head and Neck Oncology Research Conference
Journal: JNCI Journal of the National Cancer Institute (1987)

Journal Article Second International Head and Neck Oncology Research Conference Get access JNCI: Journal of the National Cancer Institute, Volume 78, Issue 4, April 1987, Page 785, https://doi.org/10.1093/jnci/78.4.785-e Published: 01 April 1987
THE LEPER-PRIEST OF SURINAM.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum Lactic Dehydrogenase, Leucine Aminopeptidase, and 5-Nucleotidase Activity: Observations in Patients with Carcinoma of the Pancreas and Hepatobiliary Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Utility and factors associated with imaging early stage breast cancer: Are we choosing wisely?
Authors: Ana Velazquez Manana, Nina Nguyen, Carlos Rodriguez Bonilla, Theresa Shao
Journal: Journal of Clinical Oncology (2018)

e18787 Background: Breast cancer (BC) is the most common malignancy in women with estimated care costs of $20.50 billion/year by 2020. In 2012, ASCO released the Choosing Wisely Initiative which recommended against the use of routine imaging in patients with newly diagnosed early stage BC. We examined the adherence rate and factors associated with non-adherence in patients with early stage BC treated within a large health care system. Methods: We identified all women with stage I-II BC diagnosed between January 1, 2014 and December 31, 2015 from the Cancer Registry of Mount Sinai Health System. Demographic, clinical and treatment related factors were collected. Medical records were reviewed to identify patients who had routine staging scan. Data of initial and follow-up imaging over 1-year period were collected. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated from logistic regression models. Results: Among 733 BC patients, the median age at diagnosis was 58 (range 26-98). One hundred thirty nine patients (19%) had routine imaging with a mean number of initial scans of 1.53 and 59 (42%) patients had at least 1 subsequent scan in the 1-year follow up (range 1-4 scans/year). PET/CT was the most frequent modality, followed by CT. Medical oncologist was the ordering provider in 52% of the cases and surgical oncologist in 44.6%. Routine scan identified no cases of metastatic disease. False-positive findings were identified in 43% and incidental findings in 8% of cases. Total cost of imaging in this group was $4480/patient. Young age (<50), TN disease, tumor size >2cm and positive lymph node were associated with increased staging scan on univariate and multivariate analysis. Conclusions: Our study highlights the prevalence of unnecessary scan in up to 19% of patients with stage I-II BC. Routine imaging resulted in increased radiation exposure and additional cost of $4480/patient. The presence of T2 tumor, positive lymph node, TN disease and young age were associated with increased staging scan. Further educational efforts are needed to avoid unnecessary scans in patients with early stage BC. OR 95% CI p Age < 50 1.69 1.06-2.67 0.026 T2 2.42 1.55-3.77 0.0001 TN 3.64 2.09-6.29 <0.0001 Positive lymph nodes 5.24 3.31-8.33 <0.0001
Retina
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FROM OUT OF THE WEST
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Any Questions?
Journal: BMJ (1966)

We publish below a selection of questions and answers of general interest.Blood Levels of Tetracycline Q.-Does tetracycline given in dragees in doses of 500 mg. at 12-hourly intervals pro- vide adequate blood levels throughout the day, and is such a dosage effective clinically ?A.-Kunin, Dornbush, and Finland' cal- culated the half-life of chlortetracycline to be 5.6 hours, tetracycline 8.5 hours, and oxy-